Systems biology approaches to novel Tumour Suppressors
Cells contain in-built checkpoint mechanisms to halt division when cells are somehow compromised in their ability to replicate properly, allowing time to repair or adjust the inflicted machinery. If the damage signal persists, cel...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BFU2009-11682
ESTRUCTURA DINAMICA Y VARIABLE DE TETRAMEROS DE P53 UNIDOS A...
151K€
Cerrado
PID2021-127710OB-I00
DEFINIR LOS PROCESOS CELLULARES A TRAVES DE LOS CUALES EL P5...
230K€
Cerrado
BFU2009-09074
IDENTIFICACION DE MECANISMOS CAUSANTES DE CANCER Y METASTASI...
593K€
Cerrado
SAF2009-08605
IDENTIFICACION Y CARACTERIZACION DE GENES IMPLICADOS EN EL P...
151K€
Cerrado
NOREL
In Vitro and in Vivo Screens for Novel Regulators in Leukemi...
220K€
Cerrado
HCC EPIGENETICS
Epigenetic Deregulation of Apoptotic Gene Expression in Hepa...
100K€
Cerrado
Información proyecto SYSTUMS
Líder del proyecto
HELSINGIN YLIOPISTO
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
100K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Cells contain in-built checkpoint mechanisms to halt division when cells are somehow compromised in their ability to replicate properly, allowing time to repair or adjust the inflicted machinery. If the damage signal persists, cells eventually undergo irreversible cellular faiths, including cellular senescence or apoptosis. Of interest to cancer researchers, apoptosis and senescence upon prolonged oncogene activation or loss of tumor suppression is an emerging paradigm, and is even detected in early stage human tumors. I reasoned that a senescence screen should reveal novel cancer genes, and undertook a kinome siRNA screen employing a cell based morphology screen in diploid, untransformed epithelial cells. One of the candidate tumor suppressors thus identified was the EPHA3 receptor tyrosine kinase gene, which is found to be frequently mutated in human lung and colorectal cancers in several cancer genome sequencing efforts. However the details of how receptor mutation contributes to tumour formation remain unclear. We aim to further explore these research angles through studying molecular networks around and cell system responses to the manipulation of EphA3 receptor signalling. Considering the role of Eph receptors in cell shape and migration, it will be essential to study its putative tumour suppressive functions in a system resembling in vivo architecture. The integration of molecular, cell biological and epithelial cellular system approaches with genomic profiling will add to our understanding of this poorly studied cancer pathway. Furthermore, an understanding of checkpoint responses to cancer mutations, including EphA3 pathway alterations, may enable us to shift responses towards apoptosis or prevent checkpoint escape and reveal cancer prevention strategies.